Cargando…
Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). METHODS: The study included patients with schizophrenia and related psychotic di...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411314/ https://www.ncbi.nlm.nih.gov/pubmed/34212530 http://dx.doi.org/10.1002/npr2.12192 |
_version_ | 1783747277319307264 |
---|---|
author | Kishi, Taro Sakuma, Kenji Okuya, Makoto Hatano, Masakazu Iwata, Nakao |
author_facet | Kishi, Taro Sakuma, Kenji Okuya, Makoto Hatano, Masakazu Iwata, Nakao |
author_sort | Kishi, Taro |
collection | PubMed |
description | AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). METHODS: The study included patients with schizophrenia and related psychotic disorders who commenced LAI‐SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan. RESULTS: We conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone‐LAI groups, respectively, discontinued due to AEs since the start of LAI‐SGA therapy. Three patients required hospitalization for AE treatment. CONCLUSION: The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results. |
format | Online Article Text |
id | pubmed-8411314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84113142021-09-03 Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review Kishi, Taro Sakuma, Kenji Okuya, Makoto Hatano, Masakazu Iwata, Nakao Neuropsychopharmacol Rep Micro Reports AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). METHODS: The study included patients with schizophrenia and related psychotic disorders who commenced LAI‐SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan. RESULTS: We conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone‐LAI groups, respectively, discontinued due to AEs since the start of LAI‐SGA therapy. Three patients required hospitalization for AE treatment. CONCLUSION: The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results. John Wiley and Sons Inc. 2021-07-01 /pmc/articles/PMC8411314/ /pubmed/34212530 http://dx.doi.org/10.1002/npr2.12192 Text en © 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Micro Reports Kishi, Taro Sakuma, Kenji Okuya, Makoto Hatano, Masakazu Iwata, Nakao Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review |
title | Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review |
title_full | Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review |
title_fullStr | Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review |
title_full_unstemmed | Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review |
title_short | Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review |
title_sort | outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: a chart review |
topic | Micro Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411314/ https://www.ncbi.nlm.nih.gov/pubmed/34212530 http://dx.doi.org/10.1002/npr2.12192 |
work_keys_str_mv | AT kishitaro outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview AT sakumakenji outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview AT okuyamakoto outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview AT hatanomasakazu outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview AT iwatanakao outcomesofpatientswithschizophreniawhodiscontinuedlongactinginjectableantipsychotictherapyduetoadverseeventsachartreview |